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Hemolytic disease of the fetus and newborn 
owing to anti-U, successfully treated with 
repeated intrauterine transfusions
J. Strindberg, J. Lundahl, and G. Ajne
Hemolytic disease of the fetus and newborn (HDFN) owing to 
anti-U has rarely been reported. U is part of the MNS system. 
M and N glycoproteins are located on glycophorin A (GPA); S 
and s antigens are on glycophorin B (GPB). Individuals who lack 
GPB are S– and s– and also lack U. The U– phenotype occurs 
almost exclusively in the African population and has a very low 
frequency (0.25%). Anti-U is of immunoglobulin G class and can 
cause hemolytic transfusion reaction and HDFN. In this report 
we present the use of a noninvasive method to detect anemia 
in the fetus and the subsequent use of intrauterine transfusion 
(IUT) with blood of a very rare phenotype. For the first time, we 
used deglycerolized and 3-week-old red blood cell units for IUT 
without signs of adverse reactions and with the expected effect on 
the hemoglobin value. We conclude that this transfusion strategy 
could be applied safely. Immunohematology 2013;29:51–
54.
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We found no detailed reports of possible deviations from 
routine blood requirements and transfusion practices for 
intrauterine transfusion (IUT) of blood components in the 
literature. We therefore propose that this case report could be 
of value when decisions concerning transfusion strategy in 
similar clinical situations are needed.
Case Report
Anti-U was identified at the International Blood Group 
Reference Laboratory (IBGRL) in Bristol, United Kingdom, in 
blood samples from a group A, D+ woman of Somalian origin 
during her third pregnancy. The anti-U titer increased from 
1 to 256, and the monocyte monolayer assay (MMA) result 
increased from 0 percent to 50 percent during this pregnancy. 
MMA is a qualitative test routinely used to establish the 
clinical significance of the antibody, in either transfusion or 
hemolytic disease of the fetus and newborn (HDFN).1 Low-
ionic-strength saline (LISS), indirect antiglobulin, and gel 
methods from Diamed, Switzerland, were used for antibody 
detection, antibody titration, and crossmatching and for the 
direct antiglobulin test (DAT). The newborn needed two 
exchange transfusions.
In gestational week 15 of the woman’s fourth pregnancy, 
the anti-U titer was 256, and the MMA was 50 percent without 
fresh complement. Genomic typing in the Centre National 
de Référence pour les Groupes Sanguins in Paris revealed a 
deletion of the GYPB gene and no glycophorin B on the red 
blood cell (RBC) surface.
The anti-U titer was monitored regularly and remained 
stable at 256. RBC antibody screening was performed to detect 
the presence of additional antibodies throughout the course of 
the pregnancy. Alloadsorption was performed on two of these 
occasions, and at gestational week 28 a blood sample was 
analyzed at the IBGRL in Bristol. No additional antibodies 
were detected.
When obstetric history and antibody levels indicate risk 
for fetal anemia, the pregnancy is monitored with Doppler 
assessment of the peak systolic velocity (PSV) in the fetal 
middle cerebral artery (MCA). Values greater than 1.5 times 
the median of the MCA PSV were used as the threshold for 
fetal intervention with IUT.
The MCA PSV was significantly increased at gestational 
weeks 26 and 27, indicating signs of anemia (Fig. 1).
A sample from the umbilical vein showed the fetus to be 
group A, D+ and U+, and DAT positive with a hemoglobin (Hb) 
of 7.2 g/dL. Only anti-U was detected in an eluate prepared 
from the umbilical sample.
The need for blood for the mother during delivery, for the 
IUT of the fetus, and for exchange transfusion of the newborn 
was assessed. Autologous transfusions were excluded because 
the Hb of the mother was slightly less than 11.0 g/dL. The 
National Frozen Blood Bank in Liverpool, French Rare 
Donor Registry, and Blood Center Skane, Sweden, were able 
to provide fresh and frozen U– blood. All blood components 
given to fetuses and newborns are irradiated.
IUT was performed under aseptic conditions and with 
ultrasound guidance; a 22-gauge needle was inserted into the 
intravascular space of the fetus using free-hand technique. 
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The choice of the fetal vessel to be used was dependent on 
the appearance of the fetus, umbilical cord, and placenta 
at the time of each transfusion. Usually the cord insertion 
was preferred, but alternatively the intrahepatic part of the 
umbilical vein was the vessel of choice after fetal analgesia and 
paralysis. Premedication of the mother was not used.
The first IUT with a deglycerolized O, D+, U– RBC unit 
was performed at 28 weeks’ gestation. Hb was 11.8 g/dL 
after the transfusion. The second IUT was performed at 30 
weeks’ gestation with a group O, D+, U– fresh washed RBC 
unit; Hb was 7.5 g/dL before and 13.5 g/dL after. The third 
IUT was performed at 32 weeks’ gestation with a 3-week-old 
washed U– RBC unit; Hb was 7.9 g/dL before, but no sample 
was tested after. The fourth IUT was performed at 34 weeks’ 
gestation with a group A, D+, U– deglycerolized RBC unit. 
Hb was 8.6 g/dL before, and no sample was tested after. All 
four units had a hematocrit between 70 and 75 percent. We 
regularly use fresh blood, less than 5 days old, for IUT, but in 
the present case we had to transfuse both deglycerolized RBCs 
and units 1 to 3 weeks of age. All units were transfused with 
no sign of adverse events and with the expected effect on Hb. 
There was no need for blood transfusion for the mother during 
delivery.
Results
Delivery was induced at 36 weeks’ gestation. A healthy 
boy was born with normal weight; his Apgar score was 10 at 
1 minute, Hb was 11.5 g/dL (normal range 13.0–20.0 g/dL), 
bilirubin was 76 μmol/L (normal range <200 μmol/L), and 
DAT was negative. His RBCs tested as S– s– (owing to the 
transfused cells), and anti-U with a titer of 16 was identified 
in the plasma. The newborn was treated with UV light from 3 
hours of age until 32 hours and from 48 hours until 78 hours, 
a total of 59 hours. Hemoglobin, bilirubin, and reticulocytes 
were measured daily (see Fig. 2).
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Fig. 1 Middle cerebral artery (MCA) peak systolic velocity (PSV) at 26, 27, 28, 29, 30, 32, 33, and 35 weeks’ gestation. At 26 and 27 weeks’ 
gestation, MCA PSV was significantly increased, indicating anemia.
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HDFN due to anti-U
Fig. 2 The development of plasma (P) bilirubin, whole blood (B) hemoglobin, and whole blood (B) reticulocyte values from date of birth 
September 9, 2010, to November 25, 2010.
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The newborn’s Hb was between 11.5 g/dL and 11.9 g/dL 
for the first 12 days. Sample taken on the 16th day showed an 
Hb of 8.5 g/dL and an anti-U titer of 2 and was DAT positive 
but still S–s–. At the age of 3 weeks (October 14, 2010) his 
Hb was 7.7 g/dL, bilirubin was 61 μmol/L, reticulocytes were 
101 × 109/L, and anti-U titer was 1. The newborn showed 
symptoms of anemia with fatigue and drowsiness, and he was 
transfused with a 5-week-old U– RBC unit. His potassium 
level was 5.5 mmol/L after transfusion (normal range 3.4–6.0 
mmol/L). At 2 months of age, the Hb was 10.4 g/dL (normal 
range 10.0–16.0 g/dL), and the boy was healthy with normal 
growth.
Discussion
Anti-U is extremely unusual; there are very few case 
reports of it in pregnancy and HDFN,2,3,4 and none of them 
report IUT, only exchange transfusion and UV light treatment. 
To provide blood for IUT, units were collected at the Skane 
Blood Center in Sweden as well as in England and France. 
The fetus exhibited anemia and needed IUT four times; 
after birth the newborn was treated with intensive UV light 
treatment for 3 days, but did not require exchange transfusion. 
At 3 weeks of age, symptoms of anemia occurred and a single 
unit of RBCs was needed. The RBCs were 5 weeks old, and 
produced the expected effect on Hb. We usually provide blood 
less than 1 week old to newborns.
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Conclusion
The impact of the age of transfused units in IUT is not 
generally discussed. We had to perform IUT using both 
deglycerolized RBC units and units of 3 to 5 weeks of age; they 
were transfused with the expected effect on Hb and without 
adverse events. We could also use units of group A as both 
mother and fetus were group A. We had the opportunity to 
follow the effect of an unusual immunization on the fetus 
and the development of anemia in the neonatal period. Early 
detection and treatment of anemia in the fetus is of great value, 
and it reduces the need for exchange transfusion in the neonatal 
period. Our report also shows that well-organized cooperation 
among international blood centers is a prerequisite for the 
successful outcome for the child.
References
 1. Nance S, Nelson J, Horenstein J, Arndt P, Platt L, Garratty G. 
Monocyte monolayer assay: an efficient noninvasive technique 
for predicting the severity of hemolytic disease of the newborn. 
Am J Clin Pathol 1989;92:89–92.
Immunohematology is on the Web!
www.redcross.org/about-us/publications/
immunohematology
For more information, send an e-mail to  
immuno@usa.redcross.org
For information concerning the National Reference 
Laboratory for Blood Group Serology, including the American 
Rare Donor Program, contact Sandra Nance, by phone at 
(215) 451-4362, by fax at (215) 451-2538, or by e-mail at 
Sandra.Nance@redcross.org
Attention:  
State Blood Bank Meeting Organizers
If you are planning a state meeting and would like copies 
of Immunohematology for distribution, please send request, 
4 months in advance, to immuno@redcross.org
Notice to Readers
All articles published, including communications and book 
reviews, reflect the opinions of the authors and do not 
necessarily reflect the official policy of the American Red 
Cross.
 2. Smith G, Knott P, Rissik J, de la Fuente J, Win N. Anti-U 
and haemolytic disease of the fetus and newborn. Br J Obstet 
Gynaecol 1998;105:1318–21.
 3. Austin TKL, Finkelstein J, Okada DM, Myhre B, Sturgeon P. 
Letter: hemolytic disease of the newborn infant due to anti-U. 
J Pediatr 1976;89:330–1.
 4. Dopp SL, Isham BE. Anti-U and hemolytic disease of the 
newborn. Transfusion 1983;23:273–4.
Johanna Strindberg, MD (corresponding author), Transfusion 
Medicine C2:66, Joachim Lundahl, MD, PhD, Transfusion Medicine 
and Clinical Immunology, and Gunilla Ajne, MD, PhD, Clinic of 
Obstetrics and Gynaecology, Karolinska University Hospital, 
Huddinge, S-141 86 Stockholm, Sweden.
